Scarica l'app Stockscreener
46.77
2.03%
0.95
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CYTK Giù?
Forum
Previsione
Frazionamento azionario
Cytokinetics Inc Borsa (CYTK) Ultime notizie
Cytokinetics started at buy by Stifel, aficamten highlighted - Seeking Alpha
Cytokinetics (NASDAQ:CYTK) Now Covered by Analysts at Stifel Nicolaus - MarketBeat
Cantor Fitzgerald Forecasts Cytokinetics FY2025 Earnings - MarketBeat
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Stifel starts Cytokinetics stock with Buy, $80 target - MSN
Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus.com
Stifel starts Cytokinetics stock with Buy, $80 target By Investing.com - Investing.com UK
Cytokinetics' (CYTK) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction - Yahoo Finance
Cytokinetics' SWOT analysis: aficamten's potential drives stock outlook - Investing.com
Cytokinetics' SWOT analysis: aficamten's potential drives stock outlook By Investing.com - Investing.com Canada
Cytokinetics (NASDAQ:CYTK) Given "Market Outperform" Rating at JMP Securities - MarketBeat
S&P 500 Futures Rise in Premarket Trading; Trump Media & Tech, Cytokinetics Lag - Barron's
Cytokinetics Announces 2025 Corporate Milestones and Vision 2030 - GlobeNewswire
Cytokinetics Sets FDA Review Date for Aficamten, Unveils Ambitious 2030 Global Expansion Plan - StockTitan
HC Wainwright Reiterates “Buy” Rating for Cytokinetics (NASDAQ:CYTK) - Defense World
Cytokinetics EVP sells shares worth $98,640 By Investing.com - Investing.com South Africa
Cytokinetics EVP sells shares worth $98,640 - Investing.com India
Cytokinetics (NASDAQ:CYTK) Sets New 1-Year LowTime to Sell? - MarketBeat
Insider Selling: Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells 2,000 Shares of Stock - MarketBeat
Cytokinetics (NASDAQ:CYTK) Receives Buy Rating from HC Wainwright - MarketBeat
Cytokinetics stock hits 52-week low at $45.59 amid market challenges - Investing.com Canada
Vanguard Group Inc's Strategic Acquisition of Cytokinetics Inc S - GuruFocus.com
Cytokinetics’ SWOT analysis: aficamten progress boosts stock outlook By Investing.com - Investing.com Nigeria
Cytokinetics' SWOT analysis: aficamten progress boosts stock outlook - Investing.com
Cytokinetics' SWOT analysis: aficamten progress boosts stock outlook By Investing.com - Investing.com Canada
Congestive Heart Failure Market Expected to rise, 2034 | Novartis, Boehringer Ingelheim, Eli Lilly, Bayer, Merck, AstraZeneca, Amgen, Otsuka Pharmaceutical, Cytokinetics, Mesoblast, Novo Nordisk - Barchart
Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Cytokinetics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
10 Clinical Trials Of 2024 – Hits, Misses And Some In Between - News & Insights
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Cytokinetics Awards Stock Grants to New Employees, Including Options and Performance Units - StockTitan
Nvidia Corp (NVDA-Q) QuotePress Release - The Globe and Mail
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by Principal Financial Group Inc. - MarketBeat
S&P 500 Futures Drop in Premarket Trading; Sportradar Group, Cytokinetics Lead - MarketWatch
Cytokinetics Initiates Confirmatory Study on Heart Failure Drug - MSN
Cytokinetics' aficamten application validated by EU regulators - MSN
Cytokinetics' potential blockbuster heart drug flips to new partner in China - The Business Journals
Cytokinetics' Heart Drug Aficamten Advances with EMA Validation for Key European Review - StockTitan
Cytokinetics, Incorporated Announces Executive Changes - Marketscreener.com
Cytokinetics (CYTK) Stock Rises on New Licensing Deal - GuruFocus.com
Why Cytokinetics Stock Was a Nearly 5% Winner Today - MSN
Spinal Muscular Atrophy Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and MOA, ROA by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme Corp - The Globe and Mail
Cytokinetics stock rises on Sanofi's rights acquisition By Investing.com - Investing.com Canada
HC Wainwright Reiterates "Buy" Rating for Cytokinetics (NASDAQ:CYTK) - MarketBeat
Sanofi: acquisition of aficamten rights for China - Marketscreener.com
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China - The Manila Times
Cytokinetics, Incorporated Announces Sanofi Acquires Exclusive Rights to Develop and Commercialize Aficamten from Corxel Pharmaceuticals - Marketscreener.com
Calculating The Fair Value Of Cytokinetics, Incorporated (NASDAQ:CYTK) - Yahoo Finance
Franklin Resources Inc. Sells 1,820,114 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
1.43%
7.41%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):